Caribou Biosciences (CRBU) reported better-than-expected earnings in the first quarter, with top and bottom-line beats.

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Stock analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Caribou ...

Decades of data following the migratory patterns of endangered caribou show that migration areas have decreased significantly ...

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.39 per share a year ago. These ...

Brookline Capital Management dropped their FY2029 EPS estimates for Caribou Biosciences in a report released on Tuesday, March 11th. Brookline Capital Management analyst L. Cann now forecasts that the ...

March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company BERKELEY, Calif., Feb. 18, 2025 (GLOBE ...

Caribou residents could pay higher property taxes if more isn’t cut from proposed 2025 expenses. City councilors discussed a potential $1.2 million shortfall in revenues that could mean raising the ...

CFO Scott Kennedy will take on the interim leadership role when John Butcher steps down from his position on March 14.